Molecular basis of Japanese variants of pyrimidine 5′-nucleotidase deficiency

被引:20
作者
Kanno, H [1 ]
Takizawa, T
Miwa, S
Fujii, H
机构
[1] Tokyo Womens Med Univ, Dept Transfus Med & Cell Proc, Tokyo 1628666, Japan
[2] Aichi Human Serv Ctr, Inst Dev Res, Dept Mol Neurobiol, Aichi, Japan
[3] Okinaka Mem Inst Med Res, Tokyo, Japan
关键词
haemolytic anaemia; erythroenzymopathy; alternative splicing; proteasome; proteolysis;
D O I
10.1111/j.1365-2141.2004.05029.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The type-I isoform of pyrimidine 5'-nucleotidase (P5N-I) has an important role in the catabolism of pyrimidine mononucleotides during erythroid maturation. Two alternatively spliced forms of P5N-I mRNA have been identified, and we found another alternatively spliced form in reticulocytes, which included an additional 87-bp sequence. The sequence is located 6.2-kb downstream of the exon 2 and 2.7-kb upstream of the exon 3 sequence; consequently, the P5N-I gene encodes 11 exons, which span approximately 48 kb. We identified five novel mutations in nine families with P5N-I deficiency: two missense mutations (425C, 721C), one splice mutation (339C), one 1-bp insertion (251-insA-252) and one 9-bp deletion (del 192-200). All patients were homozygous for each mutation. The mutant P5N-I with 721C (G241R) had lower affinity for cytidine monophosphate, suggesting that Gly241 is important for substrate binding. Haplotype analysis showed that 721C, which had been identified in five unrelated families, was a founder mutation. The mutant P5N was then expressed in Cos-7. The degradation of P5N with 425C (L142P) was significantly faster than a wild-type control, and proteasome inhibitors restored the stability of L142P. These data suggest that L142P increases susceptibility to the degradation by the ubiquitin-proteasome pathway.
引用
收藏
页码:265 / 271
页数:7
相关论文
共 33 条
[1]   Human erythrocyte pyrimidine 5′-nucleotidase, PN-I, is identical to p36, a protein associated to lupus inclusion formation in response to α-interferon [J].
Amici, A ;
Emanuelli, M ;
Raffaelli, N ;
Ruggieri, S ;
Saccucci, F ;
Magni, G .
BLOOD, 2000, 96 (04) :1596-1598
[2]   HOMOGENEOUS PYRIMIDINE NUCLEOTIDASE FROM HUMAN ERYTHROCYTES - ENZYMATIC AND MOLECULAR-PROPERTIES [J].
AMICI, A ;
EMANUELLI, M ;
FERRETTI, E ;
RAFFAELLI, N ;
RUGGIERI, S ;
MAGNI, G .
BIOCHEMICAL JOURNAL, 1994, 304 :987-992
[3]   Molecular characterization of Turkish patients with pyrimidine 5′ nucleotidase-I deficiency [J].
Balta, G ;
Gumruk, F ;
Akarsu, N ;
Gurgey, A ;
Altay, C .
BLOOD, 2003, 102 (05) :1900-1903
[4]   INTERNATIONAL COMMITTEE FOR STANDARDIZATION IN HEMATOLOGY - RECOMMENDED METHODS FOR RED-CELL ENZYME ANALYSIS [J].
BEUTLER, E ;
BLUME, KG ;
KAPLAN, JC ;
LOHR, GW ;
RAMOT, B ;
VALENTINE, WN .
BRITISH JOURNAL OF HAEMATOLOGY, 1977, 35 (02) :331-340
[5]  
BEUTLER E, 1976, J LAB CLIN MED, V88, P328
[6]  
BEUTLER E, 1980, BLOOD, V56, P251
[7]   Molecular characterization of six unrelated Italian patients affected by pyrimidine 5′-nucleotidase deficiency [J].
Bianchi, P ;
Fermo, E ;
Alfinito, F ;
Vercellati, C ;
Baserga, M ;
Ferraro, F ;
Guzzo, I ;
Rotoli, B ;
Zanella, A .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 122 (05) :847-851
[8]   Chronic non-spherocytic haemolytic anaemia due to congenital pyrimidine 5′ nucleotidase deficiency:: 25 years later [J].
Corrons, JLVI .
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2000, 13 (01) :103-118
[9]  
HIRONO A, 1983, CLIN CHIM ACTA, V130, P189
[10]   CHROMATOGRAPHIC ANALYSIS OF HUMAN-ERYTHROCYTE PYRIMIDINE 5'-NUCLEOTIDASE FROM 5 PATIENTS WITH PYRIMIDINE 5'-NUCLEOTIDASE DEFICIENCY [J].
HIRONO, A ;
FUJII, H ;
NATORI, H ;
KUROKAWA, I ;
MIWA, S .
BRITISH JOURNAL OF HAEMATOLOGY, 1987, 65 (01) :35-41